Patient reported outcomes in high risk and advanced melanoma patients

Still little is known about the long term effect of the different immunotherapies on psychosocial outcomes in high risk melanoma and advanced melanoma survivors. Collecting patient-reported outcomes (PROs) and health-related quality of life (HRQoL) data is important for understanding the short term and long term impact of melanoma itself and the treatment with ICIs on quality of life outcomes in melanoma patients. Therefore, in this study prospectively enrolling, monocenter cohort study in melanoma patients eligible for undergoing ICI treatment, we want to do more research into patient reported outcomes, what is necessary to identify personal care needs and contribute to the development of appropriate supportive care to optimize melanoma patients’ wellbeing and HRQoL. Study outcomes will be obtained via PRO questionnaires. Primary outcome is to assess short- and long-term HRQoL in high risk and advanced melanoma patients treated with immune checkpoint-inhibitors. Secondary outcomes are to describe short- and long-term anxiety and depression; fear of cancer recurrence; melanoma-specific HRQoL; symptoms and work ability in high risk and advanced melanoma patients treated with immune checkpoint-inhibitors.

No hypothesis due to the explorative character of the study

11 questionnaires distributed over 5 years (baseline, first year FU every 3 months, year two and three of FU every 6 months, year four and five of FU yearly.

N/A